Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38,267 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phase 1 Clear all
Recruiting Phase 1 Interventional

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

NCT05794958
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions
Axicabtagene Ciloleucel
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 8, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

NCT05712278
View directory record Official record
Conditions
Acute Myeloid Leukaemia
Interventions
SAR445419, fludarabine, cytarabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Omaha, Nebraska • The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 8, 2026, 5:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

NCT02440685
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer, Neoplasm, Tumor, Lymphoma, Malignant, Lymphoma, B-cell, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B Cell, Myelofibrosis, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, Lymphoma, T Cell, Peripheral, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Peripheral
Interventions
ASN002 Dose Escalation, ASN002 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

NCT01658878
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Sorafenib, Ipilimumab, Cabozantinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 8, 2026, 5:41 PM EDT
Terminated Phase 1Phase 2 Interventional

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

NCT00243035
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, tipifarnib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 8, 2026, 5:41 PM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

NCT02287025
View directory record Official record
Conditions
Physician Education
Interventions
Regorafenib (Stivarga, BAY73-4506), iPAD application, Bayer specialist
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Anaheim, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Sep 8, 2026, 5:41 PM EDT
Enrolling by invitation Phase 1 Interventional

Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

NCT04399876
View directory record Official record
Conditions
Prostate Cancer, Radical Prostatectomy
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
22 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

NCT07487740
View directory record Official record
Conditions
Healthy Participants
Interventions
NAL ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional

Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors

NCT00060268
View directory record Official record
Conditions
Esophageal Cancer
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 8, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

NCT03896568
View directory record Official record
Conditions
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
Interventions
Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

NCT00003018
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dipyridamole, fluorouracil, leucovorin calcium, mitomycin C
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

NCT00569010
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Azacitidine, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 8, 2026, 5:41 PM EDT
Not listed Phase 1 Interventional

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT05743010
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
APL-1401, Placebo
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Corona, California • Tampa, Florida • Marrero, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

NCT01270724
View directory record Official record
Conditions
CNS Germ Cell Tumor
Interventions
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 8, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery

NCT00335959
View directory record Official record
Conditions
Gastric Cancer
Interventions
capecitabine, oxaliplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
75
States / cities
Little Rock, Arkansas • Burbank, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

NCT02309580
View directory record Official record
Conditions
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
Interventions
Ibrutinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

NCT02454179
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
pembrolizumab, Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 8, 2026, 5:41 PM EDT
Recruiting Phase 3 Interventional

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
ZL-1310, Investigator's Choice of Therapy
Drug
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02509546
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
8-Chloroadenosine, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 8, 2026, 5:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

NCT03725761
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 8, 2026, 5:41 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

NCT00867061
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
ON 01910.Na Concentrate
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Sep 8, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

NCT00250042
View directory record Official record
Conditions
Leukemia, Other, Cancer
Interventions
Gleevec and Arsenic Trioxide
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 8, 2026, 5:41 PM EDT